OniX OnPoint Issue #47: Beyond the Checkpoint
Pioneering Next-Generation Immunotherapy Innovations
Welcome to this special edition of OniX OnPoint, where we explore the cutting-edge developments transforming cancer immunotherapy beyond traditional checkpoint inhibitors. As the field evolves past the foundational success of PD-1 and CTLA-4 blockade, researchers worldwide are pioneering innovative approaches to unlock the full potential of immune-mediated cancer treatment. This edition showcases breakthrough technologies from leading institutions and emerging biotech companies that are redefining how we target, deliver, and enhance immunotherapy effectiveness.
Keep reading with a 7-day free trial
Subscribe to OniX OnPoint Newsletter to keep reading this post and get 7 days of free access to the full post archives.